Reviva Pharmaceuticals Holdings, Inc. RVPH
As ofNov 20, 2026, 3:57 PM EST
- YTD
- -94.96%
- 1 year
- -97.07%
- Market cap
- 3.68M
- EPS (ttm)
- -0.39
- Shares out
- 45.44M
- Forward P/E
- -2.02
- YTD return
- -94.96%
- 1-year return
- -97.07%
- 50-day average
- 1.37
- 200-day average
- 1.70
- Enterprise value
- 27.57M
- Volume
- 5.46K
- Avg volume
- 29.02K
- Open
- 0.2905
- Previous close
- 0.284
- Day's range
- 0.281 – 0.33495
- 52-week range
- 0.281 – 14.60
- Beta
- -0.06
- Analysts
- Buy
- Price target
- 14.80 (+5166.9%)
Key statistics
- Price / book
- 8.00
- Free cash flow
- -17.42M
- Total cash
- 6.18M
- Total debt
- 207.50K
- Short % of float
- 18.59%
Fundamental scorecard
5 of 25 checks passed on RVPH’s reported financials
5of 25 checks passed
- Value 1 of 5
- Growth 1 of 5
- Profitability 0 of 5
- Financial health 3 of 5
- Dividend 0 of 5
Statements to Mar 31, 2026.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 14, 2024 | Sep 1, 2024 | -0.23 | -0.25 | -0.02 | -8.70% |
| Aug 14, 2024 | Jun 1, 2024 | -0.28 | -0.26 | +0.02 | +7.14% |
| Aug 14, 2024 | Jun 1, 2024 | -0.28 | — | — | — |
| May 14, 2024 | Mar 1, 2024 | -0.28 | -0.25 | +0.03 | +10.71% |
| May 14, 2024 | Mar 1, 2024 | -0.28 | — | — | — |
| Apr 15, 2024 | Dec 1, 2023 | 0.00 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 14, 2024 | D. Boral Capital | main | Buy | Buy |
| Nov 13, 2024 | D. Boral Capital | main | Buy | Buy |
| Sep 23, 2024 | EF Hutton | init | — | Buy |
| Aug 26, 2024 | Benchmark | reit | Speculative Buy | Speculative Buy |
| Aug 16, 2024 | Maxim Group | down | Buy | Hold |
| Jul 11, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
About Reviva Pharmaceuticals Holdings, Inc.
Reviva Pharmaceuticals Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis. It is also developing RP1208 for the treatment of depression and obesity. Reviva Pharmaceuticals Holdings, Inc. was founded in 2018 and is headquartered in Cupertino, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- revivapharma.com
News
Your note
Sign in to keep a note on RVPH — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Armistice Capital, LLC | 9.53% | 3,186,000 | 5.23M | Sep 29, 2024 |
| Millennium Management Llc | 5.48% | 1,832,814 | 3.01M | Sep 29, 2024 |
| Schonfeld Strategic Advisors Llc | 4.53% | 1,515,900 | 2.49M | Sep 29, 2024 |
| Vanguard Group Inc | 3.07% | 1,025,249 | 1.68M | Sep 29, 2024 |
| Woodline Partners LP | 2.05% | 684,805 | 1.12M | Sep 29, 2024 |
| Parkman Healthcare Partners LLC | 1.53% | 512,202 | 840.01K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.09% | 700,442 | 1.15M | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 0.93% | 312,304 | 512.18K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.44% | 146,870 | 240.87K | Oct 30, 2024 |
| iShares Micro Cap ETF | 0.16% | 51,984 | 85.25K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.14% | 47,139 | 77.31K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.10% | 34,759 | 57.00K | Oct 30, 2024 |
